Viking Therapeutics (VKTX) Share-based Compensation (2014 - 2026)

Viking Therapeutics has disclosed Share-based Compensation across 13 years of filings, most recently posting $10.3 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.3 million, down 8.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.8 million (up 20.34% YoY), and the FY2025 annual result was $40.8 million, up 37.38% from the prior year.
• Share-based Compensation came in at $10.3 million for Q1 2026 at Viking Therapeutics, up from $8.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q2 2025 to a low of $1.9 million in Q3 2022.
• The 5-year median for Share-based Compensation is $5.7 million (2024), against an average of $6.3 million.
• Across the five-year window, Share-based Compensation surged 130.98% in 2023 and decreased 18.33% in 2025, its largest moves.
• Viking Therapeutics' Share-based Compensation stood at $2.2 million in 2022, then jumped by 89.24% to $4.1 million in 2023, then surged by 38.9% to $5.7 million in 2024, then soared by 51.53% to $8.6 million in 2025, then rose by 20.38% to $10.3 million in 2026.
• The last three Share-based Compensation figures came in at $10.3 million (Q1 2026), $8.6 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.